Loading…
BridgeBio Pharma, Inc. is projected to rise to $87.81 by 2027, a +32% move from its current price of $66.44. BBIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $65.01 | $66.46 | $67.93 | +0.02% |
| May 30 | $64.44 | $66.47 | $68.57 | +0.05% |
| May 31 | $64.00 | $66.49 | $69.07 | +0.07% |
| Jun 1 | $63.64 | $66.50 | $69.49 | +0.10% |
| Jun 2 | $63.33 | $66.52 | $69.87 | +0.12% |
| Jun 3 | $63.05 | $66.54 | $70.22 | +0.14% |
| Jun 4 | $62.79 | $66.55 | $70.54 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $62.79 | $66.55 | $70.54 | +0.17% |
| Week 2 | $61.40 | $66.66 | $72.38 | +0.34% |
| Week 3 | $60.38 | $66.78 | $73.85 | +0.51% |
| Week 4 | $59.55 | $66.89 | $75.14 | +0.68% |
| Week 5 | $58.83 | $67.00 | $76.31 | +0.85% |
| Week 6 | $58.21 | $67.12 | $77.39 | +1.02% |
| Week 7 | $57.64 | $67.23 | $78.41 | +1.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical study for the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease.
In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc.
was founded in 2015 and is headquartered in Palo Alto, California.
BridgeBio Pharma, Inc. (BBIO) is a healthcare company focused on developing therapies for genetic diseases. It is currently priced at $69.12 per share, with a market cap of $13.54B and a market rank of 742. These metrics place the company among mid-cap healthcare firms with a focus on innovative genetic therapies.
A major floor 14.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.6% away) — a key level to hold.
The nearest ceiling, 16.9% above — a clean break opens room to run.
A major ceiling 24.4% above — clearing it would confirm fresh momentum.
Key BBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $68.36 | Sell | $67.63 | Sell |
| MA 10 | $67.75 | Sell | $67.79 | Sell |
| MA 20 | $67.97 | Sell | $68.56 | Sell |
| MA 50 | $71.10 | Sell | $70.08 | Sell |
| MA 100 | $72.01 | Sell | $69.74 | Sell |
| MA 200 | $66.18 | Buy | $64.73 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.09 | Neutral |
| Stoch RSI (14) | 55.88 | Neutral |
| CCI (20) | -69.68 | Neutral |
| Williams %R (14) | -68.57 | Info |
| MACD (12,26,9) | 0.17 | Buy |
| ROC (12) | -1.41 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 31.43 | Neutral |
| TRIX (15) | -0.28 | Sell |
| Awesome (5,34) | -2.64 | Sell |
| Ultimate (7,14,28) | 47.87 | Neutral |
| Momentum (10) | 0.49 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 68.66 | Sell |
| ADX (14) | 14.33 | Neutral |
| ATR (14) | 1.47 | Info |
Technically, the sentiment is bullish and the near-term setup reflects a balance around the current price. RSI14 is 50, indicating neutral momentum, while the 50-day moving average sits at $71.23 and the 200-day moving average at $65.98. Support is identified at $64.68 and resistance at $77.93, framing a reasonable trading band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $63.73 | $66.44 | $91.48 | 0% | Neutral | |
| $70.96 | $87.81 | $114.28 | +32% | Bullish | |
| $84.22 | $106.47 | $142.72 | +60% | Bullish | |
| $93.72 | $120.60 | $165.51 | +82% | Bullish | |
| $98.57 | $128.85 | $180.41 | +94% | Bullish | |
| $107.35 | $142.36 | $202.85 | +114% | Bullish | |
| $112.87 | $151.67 | $219.57 | +128% | Bullish | |
| $119.66 | $162.82 | $239.13 | +145% | Bullish | |
| $137.31 | $189.04 | $281.36 | +185% | Bullish | |
| $158.57 | $220.79 | $332.71 | +232% | Bullish | |
| $201.21 | $294.68 | $467.92 | +344% | Bullish | |
| $422.76 | $674.26 | $1,156.64 | +915% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $63.73 | $66.44 | $78.24 | +0.00% |
| June 2026 | $58.52 | $68.43 | $81.71 | +3.00% |
| July 2026 | $57.69 | $67.92 | $81.99 | -0.75% |
| August 2026 | $58.15 | $68.83 | $83.79 | +1.34% |
| September 2026 | $59.69 | $70.95 | $86.97 | +3.09% |
| October 2026 | $59.53 | $71.05 | $87.63 | +0.14% |
| November 2026 | $59.13 | $70.82 | $87.83 | -0.32% |
| December 2026 | $61.08 | $73.39 | $91.48 | +3.63% |
Click any year to see its month-by-month BBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BBIO to range from $63.73 to $91.48 through 2026. The $66.44 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The BBIO price prediction for 2027 points to an average of $87.81 (low $70.96, high $114.28) — a potential gain of +32% on today's $66.44. Momentum favours further upside here.
In 2028, BBIO is projected to trade between $84.22 and $142.72, averaging $106.47 — a potential gain of +60% from today's $66.44. That is up +21% on the projected 2027 average. Buyers look set to stay in control over this stretch.
BridgeBio Pharma, Inc.'s 2029 outlook centres on $120.60, within a $93.72 to $165.51 range. That is up +13% on the projected 2028 average. That marks a +82% change versus current levels. Momentum favours further upside here.
By 2030, BBIO could reach as high as $180.41, with a base case around $128.85 and support toward $98.57 — roughly +94% from $66.44. Buyers look set to stay in control over this stretch.
Expect BBIO to range from $107.35 to $202.85 through 2031. The $142.36 average target implies a +114% move from current prices. That is up +10% on the projected 2030 average. Momentum favours further upside here.
The BBIO price prediction for 2032 points to an average of $151.67 (low $112.87, high $219.57) — a potential gain of +128% on today's $66.44. Buyers look set to stay in control over this stretch.
In 2033, BBIO is projected to trade between $119.66 and $239.13, averaging $162.82 — a potential gain of +145% from today's $66.44. That is up +7% on the projected 2032 average. Momentum favours further upside here.
BridgeBio Pharma, Inc.'s 2034 outlook centres on $189.04, within a $137.31 to $281.36 range. That is up +16% on the projected 2033 average. That marks a +185% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, BBIO could reach as high as $332.71, with a base case around $220.79 and support toward $158.57 — roughly +232% from $66.44. Momentum favours further upside here.
Expect BBIO to range from $201.21 to $467.92 through 2040. The $294.68 average target implies a +344% move from current prices. That is up +33% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The BBIO price prediction for 2050 points to an average of $674.26 (low $422.76, high $1,156.64) — a potential gain of +915% on today's $66.44. Momentum favours further upside here.
Investing $1,000 in BBIO today (≈ 15.051174 BBIO) could be worth
$10,148.39
+$9,148.39 (+915%) by 2050 · US Dollar
Based on the average projected BBIO price of $674.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BBIOwould be worth at today's price.
$1,000 invested in BBIO on May 27, 2025 (≈ 30.211482 BBIO) would be worth
$2,007.25
+$1,007.25 (+100.7%) today · 2.01× · US Dollar
Based on a BBIO entry price of $33.1 vs. today's $66.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $68.22 | $973.91 | -2.6% |
| 1 month ago | $74.52 | $891.57 | -10.8% |
| 3 months ago | $67.61 | $982.69 | -1.7% |
| 6 months ago | $72.01 | $922.65 | -7.7% |
| 1 year ago | $33.1 | $2,007.25 | +100.7% |
| All time (5.0y) ago | $60.37 | $1,100.55 | +10.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BBIO forecast.
Our base-case forecast reaches $130.00 around 2031.
Implied market cap at $130.00: $25.46B
The multi-year forecast shows a bullish trajectory with a neutral start in 2026 (avg $69.12, min $63.73, max $96.59; ROI 0) and a clear rising path thereafter. By 2027 the avg is $92.56 with a 33.9% ROI, climbing further each year to 2030 where the avg reaches $136.71 and the ROI is 97.8%, with a max of $192.23. The forecast continues its bullish pace through 2040 (avg $319.77, ROI 362.6; max $511.05) and culminates in 2050 with an avg of $741.33 and a max of $1,281.52, delivering a 972.5% ROI.
Overall, sentiment remains bullish across the horizon, though these are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $136.71, with a min of $104.21 and a max of $192.23, and an expected ROI of 97.8% with bullish sentiment.
Forecasts show bullish sentiment from 2027 onward with rising averages and ROIs (e.g., 2027 avg $92.56, ROI 33.9%; 2028 avg $112.52, ROI 62.8%; 2050 max $1,281.52, ROI 972.5%), though 2026 is neutral with average $69.12 and ROI 0.
Yes. The forecast includes year-by-year max values that exceed $200: 2031 max $217.30, 2032 max $236.82, 2033 max $256.36, 2034 max $305.52, 2035 max $363.49, with higher peaks later (2040 max $511.05, 2050 max $1,281.52).
Current price is $69.12 per share and the market cap is $13.54B.
The 30-day range runs from $59.60 to $80.17. RSI14 is 50, with SMA50 at $71.23 and SMA200 at $65.98. Support sits at $64.68 and resistance at $77.93.
BridgeBio Pharma, Inc. Community Discussion
0Share your BridgeBio Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.